Susquehanna International Group, LLP Akero Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$21.45 - $29.34 $102,960 - $140,832	4,800 Added 5.78%	87,900 $2.52 Million
Q2 2024 Aug 15, 2024	SELL	$18.31 - $24.62 $1.6 Million - $2.15 Million	-87,500 Reduced 51.29%	83,100 $1.95 Million
Q1 2024 May 07, 2024	BUY	$17.76 - $31.18 $1.2 Million - $2.1 Million	67,300 Added 65.15%	170,600 $4.31 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $11.8 Million - $52.2 Million	-1,037,200 Reduced 90.94%	103,300 $2.41 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $28.4 Million - $36 Million	688,600 Added 152.38%	1,140,500 $57.7 Million
Q2 2023 Aug 11, 2023	BUY	$36.89 - $56.88 $11.4 Million - $17.6 Million	310,300 Added 219.14%	451,900 $21.1 Million
Q1 2023 May 16, 2023	SELL	$37.27 - $50.24 $316,795 - $427,040	-8,500 Reduced 5.66%	141,600 $5.42 Million
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $6.51 Million - $10.7 Million	-194,700 Reduced 56.47%	150,100 $8.23 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $3.5 Million - $11.7 Million	344,800 New	344,800 $11.7 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.42B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.